The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Tapering of SSRI treatment to mitigate withdrawal symptoms
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Following discontinuation of a long-term treatment with paroxetine, Shoenberger [117] first reported the emergence of persistent post-withdrawal panic disorder, which was some years later also documented by Bhanji et al. [18].”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [117]
In the citing paper
“After SSRIs long-term use, persistent post-withdrawal disorders have been described [10, 13, 18, 19, 112, 117, 118].”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [117]
In the citing paper
“The potential utility of the dose/occupancy relationship in guiding tapering to mitigate withdrawal symptoms has received recent interest by multiple groups [11, 12, 15], and was considered in a recent Cochrane review on approaches to antidepressant discontinuation [14] and in a recent iteration of a major guideline on the management of patients with mood disorders [16].”
From The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review (2022) · cites this paper as [12]
In the citing paper
“As one postulated mechanism underlying antidepressant withdrawal symptoms is a rapid decrease in SERT occupancy arising when antidepressants are tapered or stopped [11, 12]”
From The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review (2022) · cites this paper as [12]
In the citing paper
“This has been suggested to be the case for antidepressants when tapering using standard available doses, especially for the last reductions before cessation due to the large biological effects even at very low and subtherapeutic doses.12,16,49”
From Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review (2022) · cites this paper as [16]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kuyken, W., Warren, F. C., Taylor, R. S., Whalley, B., Crane, C., Bondolfi, G., Hayes, R., Huijbers, M., Ma, H., Schweizer, S., et al. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.0076 · Cited by 821
Davies, J., & Read, J. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2018.08.027 · Cited by 387
Tapering of SSRI treatment to mitigate withdrawal symptoms
Horowitz, M. A., & Taylor, D. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30032-x · Cited by 280
Bockting, C. L. H., Klein, N. S., Elgersma, H. J., van Rijsbergen, G. D., Slofstra, C., Ormel, J., Buskens, E., Dekker, J., de Jong, P. J., Nolen, W. A., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30100-7 · Cited by 130
Research works printed but not linked: 1
- Groot, 2013, Taperingstrips voor paroxetine en venlafaxine, Tijdschr Psychiatr, 55, 789
Cited by
Malhi, G. S., Bell, E., Bassett, D., Boyce, P., Bryant, R., Hazell, P., Hopwood, M., Lyndon, B., Mulder, R., Porter, R., et al. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867420979353 · Cited by 614
Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265
Murphy, S. E., Capitão, L. P., Giles, S. L. C., Cowen, P. J., Stringaris, A., & Harmer, C. J. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00154-1 · Cited by 112
Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis
Henssler, J., Schmidt, Y., Schmidt, U., Schwarzer, G., Bschor, T., & Baethge, C. (2024) · The Lancet Psychiatry · doi:10.1016/s2215-0366(24)00133-0 · Cited by 106
Strategies to reduce use of antidepressants
Kendrick, T. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14475 · Cited by 107
“Independent of Horowitz and Taylor(53) but with identical reasoning, they proposed reducing doses hyperbolically, and also advocated mini-tapering.(54)”
BackgroundInfluential
Metadata
- Authors
- Ruhe, H. G., Horikx, A., van Avendonk, M. J. P., Groeneweg, B. F., & Woutersen-Koch, H.
- Affiliations
- Royal Dutch Pharmacists Association (NL)
- ORCID
- Groeneweg, Bart F
- Venue
- The Lancet Psychiatry
- Publisher
- Elsevier BV
- Published
- 2019-07
- Volume
- 6
- Issue
- 7
- Pages
- 561-562
- ISSN
- 2215-0366 (ISSN-L)
- OpenAlex
- W2953239204
- Semantic Scholar
- e540a957fbc0a8a1621226aef54eda3d32f0b978
- Cited by
- 28
- References
- 4
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 2 · 2023: 4 · 2022: 4 · 2021: 6 · 2020: 6 · 2019: 1
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- antidepressant tapering, serotonin-norepinephrine reuptake inhibitors, antidepressant discontinuation, paroxetine, venlafaxine, duloxetine, sertraline, citalopram, escitalopram, fluvoxamine, general practitioners, pharmacists, patient associations
- MeSH terms
- Humans, Substance Withdrawal Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tapering of SSRI treatment to mitigate withdrawal symptoms. https://app.cochat.ai/papers/10.1016/s2215-0366(19)30182-8
- The paper
- Ruhe, H. G., Horikx, A., van Avendonk, M. J. P., Groeneweg, B. F., & Woutersen-Koch, H. (2019). Tapering of SSRI treatment to mitigate withdrawal symptoms. The Lancet Psychiatry. https://doi.org/10.1016/s2215-0366(19)30182-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.